Meditation Accelerated Brain Stimulation for Depression
NCT: NCT04586699 · COMPLETED
Brief Summary
Repetitive Transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. The ultimate goal of this treatment is to increase excitability and long-term plasticity in DLPFC, a brain region shown to be hypo-active in depression. Unfortunately, rTMS only has low to moderate efficacy; remission rates for patients range from \~15-30% in large randomized controlled trials. The focus of this research is to develop a next-generation rTMS protocol that is guided by the basic principles underlying brain plasticity, in order to improve the efficacy of rTMS for the treatment of depression. Specifically, in this study the investigators will test rTMS paired with a depression-relevant cognitive state of internal attention.
Frequently Asked Questions
What is Meditation Accelerated Brain Stimulation for Depression?
Meditation Accelerated Brain Stimulation for Depression is a clinical trial registered under NCT04586699. Current status: COMPLETED.
What is the status of NCT04586699?
The current status of NCT04586699 (Meditation Accelerated Brain Stimulation for Depression) is: COMPLETED.
When did Meditation Accelerated Brain Stimulation for Depression start?
Meditation Accelerated Brain Stimulation for Depression started on 2021-07-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.